Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
54.49 -0.46 (-0.84%) 11:35 ET [NASDAQ]
54.48 x 29 54.52 x 5
Realtime by (Cboe BZX)
54.48 x 29 54.52 x 5
Realtime 54.43 -0.52 (-0.95%) 09:27 ET
Quote Overview for Thu, Feb 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
54.33
Day High
54.58
Open 54.45
Previous Close 54.95 54.95
Volume 465,637 465,637
Avg Vol 2,188,134 2,188,134
Stochastic %K 83.39% 83.39%
Weighted Alpha +15.32 +15.32
5-Day Change +0.39 (+0.72%) +0.39 (+0.72%)
52-Week Range 45.22 - 58.97 45.22 - 58.97
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,454,576
  • Shares Outstanding, K 2,537,845
  • Annual Sales, $ 47,922 M
  • Annual Income, $ 6,016 M
  • EBIT $ 10,112 M
  • EBITDA $ 13,993 M
  • 60-Month Beta 0.57
  • Price/Sales 3.13
  • Price/Cash Flow 10.30
  • Price/Book 1.65

Options Overview Details

View History
  • Implied Volatility 20.76% ( +0.75%)
  • Historical Volatility 20.75%
  • IV Percentile 18%
  • IV Rank 16.43%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 493
  • Volume Avg (30-Day) 909
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 26,213
  • Open Int (30-Day) 28,978

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.86
  • Number of Estimates 5
  • High Estimate 0.90
  • Low Estimate 0.84
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -10.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.14 +4.56%
on 01/29/25
Period Open: 53.34
55.20 -1.23%
on 02/26/25
+1.18 (+2.21%)
since 01/27/25
3-Month
45.80 +19.04%
on 12/16/24
Period Open: 48.72
55.20 -1.23%
on 02/26/25
+5.80 (+11.90%)
since 11/27/24
52-Week
45.22 +20.57%
on 04/18/24
Period Open: 48.21
58.97 -7.55%
on 09/04/24
+6.31 (+13.09%)
since 02/27/24

Most Recent Stories

More News
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples

Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.

NVAX : 7.80 (+6.56%)
SNY : 54.49 (-0.84%)
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic,...

ALNY : 242.79 (-0.44%)
GILD : 111.89 (+1.29%)
REGN : 714.40 (+1.06%)
SNY : 54.49 (-0.84%)
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

This week, Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s RHHBY spinal muscular atrophy...

NVS : 108.73 (+0.66%)
ABBV : 205.02 (+0.99%)
RHHBY : 41.4300 (-1.45%)
PFE : 26.20 (-0.83%)
SNY : 54.49 (-0.84%)
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over...

AZN : 76.01 (+0.65%)
MRK : 90.43 (+1.17%)
AMGN : 309.00 (+0.86%)
SNY : 54.49 (-0.84%)
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year...

REGN : 714.40 (+1.06%)
SNY : 54.49 (-0.84%)
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago...

BAYRY : 5.9400 (-1.66%)
REGN : 714.40 (+1.06%)
RHHBY : 41.4300 (-1.45%)
SNY : 54.49 (-0.84%)
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine (PCV),...

PCVX : 76.33 (-2.95%)
MRK : 90.43 (+1.17%)
PFE : 26.20 (-0.83%)
SNY : 54.49 (-0.84%)
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

This week, Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity medicine, amycretin, showed superior weight loss in a study. Merck MRK...

AZN : 76.01 (+0.65%)
NVO : 89.60 (+0.06%)
MRK : 90.43 (+1.17%)
RHHBY : 41.4300 (-1.45%)
SNY : 54.49 (-0.84%)
Sanofi (SNY) Q4 2024 Earnings Call Transcript

SNY earnings call for the period ending December 31, 2024.

SNY : 54.49 (-0.84%)
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over...

JNJ : 162.93 (-0.09%)
TEVA : 16.77 (-0.06%)
ABBV : 205.02 (+0.99%)
SNY : 54.49 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 55.87
2nd Resistance Point 55.54
1st Resistance Point 55.24
Last Price 54.49
1st Support Level 54.61
2nd Support Level 54.28
3rd Support Level 53.98

See More

52-Week High 58.97
Last Price 54.49
Fibonacci 61.8% 53.72
Fibonacci 50% 52.10
Fibonacci 38.2% 50.47
52-Week Low 45.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements